{"id":"lorazepam","rwe":[],"_fda":{"id":"22212bf6-1414-4b32-bc67-25d614c357ee","abuse":["Abuse Lorazepam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see ). The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol)."],"set_id":"00960fbd-a5da-408b-9867-62982f20906f","openfda":{"nui":["N0000175694","M0002356"],"unii":["O26FZP769L"],"route":["ORAL"],"rxcui":["197901"],"spl_id":["22212bf6-1414-4b32-bc67-25d614c357ee"],"brand_name":["Lorazepam"],"spl_set_id":["00960fbd-a5da-408b-9867-62982f20906f"],"package_ndc":["68788-7428-3","68788-7428-6","68788-7428-9","68788-7428-1","68788-7428-8"],"product_ndc":["68788-7428"],"generic_name":["LORAZEPAM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Benzodiazepines [CS]"],"substance_name":["LORAZEPAM"],"pharm_class_epc":["Benzodiazepine [EPC]"],"manufacturer_name":["Preferred Pharmaceuticals, Inc."],"application_number":["ANDA203572"],"original_packager_product_ndc":["13107-084"]},"version":"7","warnings":["WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe lorazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when lorazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see ). Abuse, Misuse, and Addiction The use of benzodiazepines, including lorazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see ). Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of lorazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of lorazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (a patient-specific plan should be used to taper the dose) (see ). Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see ). Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see ). Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. Lorazepam is not recommended for use in patients with a primary depressive disorder or psychosis. Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression (see ). As with all patients on CNS-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished. Neonatal Sedation and Withdrawal Syndrome Use of lorazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate (see ). Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to lorazepam during pregnancy for signs of withdrawal; manage these neonates accordingly."],"pregnancy":["Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including lorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal (see and Clinical Considerations ). Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data) . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly (see ). Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses."],"dependence":["Dependence Physical Dependence Lorazepam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see ). To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (see and WARNINGS ). Acute Withdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures and suicidality. Protracted Withdrawal Syndrome Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re‑-emergence or continuation of symptoms for which the benzodiazepine was being used. Tolerance Tolerance to lorazepam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of lorazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines."],"overdosage":["OVERDOSAGE Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal (see ). Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage. In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway management. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. See the flumazenil injection Prescribing Information. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations."],"description":["DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3‑-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. Chemical Structure"],"precautions":["PRECAUTIONS In patients with depression, a possibility for suicide should be borne in mind; benzodiazepines should not be used in such patients without adequate antidepressant therapy. Lorazepam should be used with caution in patients with compromised respiratory function (e.g., COPD, sleep apnea syndrome). Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg. Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued. The usual precautions for treating patients with impaired renal or hepatic function should be observed. As with all benzodiazepines, the use of lorazepam may worsen hepatic encephalopathy; therefore, lorazepam should be used with caution in patients with severe hepatic insufficiency and/or encephalopathy. Dosage for patients with severe hepatic insufficiency should be adjusted carefully according to patient response; lower doses may be sufficient in such patients. In patients where gastrointestinal or cardiovascular disorders coexist with anxiety, it should be noted that lorazepam has not been shown to be of significant benefit in treating the gastrointestinal or cardiovascular component. Esophageal dilation occurred in rats treated with lorazepam for more than 1 year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg/day). The effect was reversible only when the treatment was withdrawn within 2 months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper GI disease. Safety and effectiveness of lorazepam in children of less than 12 years have not been established. Information for Patients Advise the patient to read the FDA-approved patient labeling ( Error! Hyperlink reference not valid. ). Risks from Concomitant Use with Opioids Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when lorazepam is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see and ). Abuse, Misuse, and Addiction Inform patients that the use of lorazepam even at recommended doses, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug (see and DRUG ABUSE AND DEPENDENCE ). Withdrawal Reactions Inform patients that the continued use of lorazepam may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of lorazepam may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of lorazepam may require a slow taper (see and DRUG ABUSE AND DEPENDENCE ). Pregnancy Advise pregnant females that use of lorazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see and ). Instruct patients to inform their healthcare provider if they are pregnant. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy (see ). Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs (see ). Essential Laboratory Tests Some patients on lorazepam have developed leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy. Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an 18-month study with lorazepam. No studies regarding mutagenesis have been performed. Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including lorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal (see and Clinical Considerations ). Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data) . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly (see ). Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses. Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to lorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age (see ). Age does not appear to have a significant effect on lorazepam kinetics (see ). Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity (e.g., sedation) of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients (see DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Lorazepam Tablets, USP are available in the following dosage strengths: 1 mg, white to off-white, round, flat-faced beveled edge tablets debossed with ‘U33’ on one side and bisect on the other side. Bottles of 30 NDC 68788-7428-03 Bottles of 60 NDC 68788-7428-06 Bottles of 90 NDC 68788-7428-09 Bottles of 100 NDC 68788-7428-01 Bottles of 120 NDC 68788-7428-08 Keep bottles tightly closed. Keep out of reach of children. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as described in the USP. Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 06/2023 Repackaged by Preferred Pharmaceuticals, Inc. Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides"],"spl_medguide":["MEDICATION GUIDE Lorazepam Tablets, USP CIV (lor-A-ze-pam) What is the most important information I should know about lorazepam tablets? • Lorazepam tablets are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. Get emergency help right away if any of the following happens: o shallow or slowed breathing o breathing stops (which may lead to the heart stopping) o excessive sleepiness (sedation) Do not drive or operate heavy machinery until you know how taking lorazepam tablets with opioids affects you. • Risk of abuse, misuse, and addiction. There is a risk of abuse, misuse, and addiction with benzodiazepines including lorazepam tablets which can lead to overdose and serious side effects including coma and death. o Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including lorazepam tablets. These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects. o You can develop an addiction even if you take lorazepam tablets exactly as prescribed by your healthcare provider. o Take lorazepam tablets exactly as your healthcare provider prescribed. o Do not share your lorazepam tablets with other people. o Keep lorazepam tablets in a safe place and away from children. • Physical dependence and withdrawal reactions. Lorazepam tablets can cause physical dependence and withdrawal reactions. o Do not suddenly stop taking lorazepam tablets. Stopping lorazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual movements, responses or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms. o Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months, including anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears. o Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction. o Do not take more lorazepam tablets than prescribed or take lorazepam tablets for longer than prescribed. What are lorazepam tablets? • Lorazepam tablets are a prescription medicine used: o to treat anxiety disorders o for the short-term relief of the symptoms of anxiety or anxiety that can happen with symptoms of depression o Lorazepam tablets are a federal controlled substance (CIV) because it contains lorazepam that can be abused or lead to dependence. Keep lorazepam tablets in a safe place to prevent misuse and abuse. Selling or giving away lorazepam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs. o It is not known if lorazepam tablets are safe and effective for use in children less than 12 years of age. o It is not known if lorazepam tablets are safe and effective for use for longer than 4 months. Do not take lorazepam tablets if you: • are allergic to lorazepam, other benzodiazepines, or any of the ingredients in lorazepam tablets. See the end of this Medication Guide for a complete list of ingredients in lorazepam tablets. Before you take lorazepam tablets, tell your healthcare provider about all of your medical conditions, including if you: • have or have had depression, mood problems, or suicidal thoughts or behavior • have a history of drug or alcohol abuse or addiction • have lung disease or breathing problems (such as COPD, sleep apnea syndrome) • have liver or kidney problems • have or have had seizures • are pregnant or plan to become pregnant. o Taking lorazepam tablets late in pregnancy may cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone), and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems). o Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with lorazepam tablets. o There is a pregnancy registry for women who take lorazepam tablets during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with lorazepam tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visiting https://womensmentalhealth.org/pregnancyregistry/. • are breastfeeding or plan to breastfeed. Lorazepam passes into your breast milk. o Breastfeeding during treatment with lorazepam tablets may cause your baby to have sleepiness, feeding problems, and decreased weight gain. o Talk to your healthcare provider about the best way to feed your baby if you take lorazepam tablets. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking lorazepam tablets with certain other medicines can cause side effects or affect how well lorazepam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. How should I take lorazepam tablets? • Take lorazepam tablets exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how much lorazepam tablets to take and when to take it. • If you take too much lorazepam tablets, call your healthcare provider or go to the nearest hospital emergency room right away. What are the possible side effects of lorazepam tablets? Lorazepam tablets may cause serious side effects, including: • See “What is the most important information I should know about lorazepam tablets?” • Lorazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. o Do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam tablets affects you. o Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam tablets without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, lorazepam tablets may make your sleepiness or dizziness much worse. • Depression. Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam tablets. The most common side effects of lorazepam tablets include: • sedation • dizziness • weakness • unsteadiness These are not all the possible side effects of lorazepam tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store lorazepam tablets? • Store lorazepam tablets in a tightly closed container at room temperature between 20° to 25°C (68° to 77°F). • Keep lorazepam tablets and all medicines out of the reach of children. General information about the safe and effective use of lorazepam tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lorazepam tablets for a condition for which it was not prescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about lorazepam tablets that is written for health professionals. What are the ingredients in lorazepam tablets? Active ingredient: lorazepam Inactive ingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India For more information, call Aurobindo Pharma USA, Inc. at 1-866-850-2876. This Medication Guide has been approved by the U.S. Food and Drug Administration. Repackaged by Preferred Pharmaceuticals, Inc. Revised: 06/2023"],"boxed_warning":["WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). • The use of benzodiazepines, including lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS ). • The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage ( DOSAGE AND ADMINISTRATION and WARNINGS )."],"geriatric_use":["Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age (see ). Age does not appear to have a significant effect on lorazepam kinetics (see ). Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity (e.g., sedation) of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20250724","nursing_mothers":["Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to lorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain."],"laboratory_tests":["Essential Laboratory Tests Some patients on lorazepam have developed leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy."],"adverse_reactions":["ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects occurring with high doses. In a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). The incidence of sedation and unsteadiness increased with age. Other adverse reactions to benzodiazepines, including lorazepam are fatigue, drowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, convulsions/seizures, tremor, vertigo, eye function/visual disturbance (including diplopia and blurred vision), dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, coma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, alopecia; syndrome of inappropriate antidiuretic hormone (SIADH), hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases in blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Lorazepam is contraindicated in patients with: • hypersensitivity to benzodiazepines or to any components of the formulation • acute narrow-angle glaucoma."],"drug_interactions":["Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam."],"spl_medguide_table":["<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><col width=\"98%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">MEDICATION GUIDE</content> <content styleCode=\"bold\">Lorazepam Tablets, USP CIV</content> <content styleCode=\"bold\">(lor-A-ze-pam)</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about lorazepam tablets?</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Lorazepam tablets are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.</content> Get emergency help right away if any of the following happens: <list listType=\"unordered\"><item><caption>o</caption>shallow or slowed breathing</item><item><caption>o</caption>breathing stops (which may lead to the heart stopping)</item><item><caption>o</caption>excessive sleepiness (sedation)</item></list></item></list><paragraph>   Do not drive or operate heavy machinery until you know how taking lorazepam tablets with opioids affects you. </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Risk of abuse, misuse, and addiction. </content>There is a risk of abuse, misuse, and addiction with benzodiazepines including lorazepam tablets which can lead to overdose and serious side effects including coma and death. <list listType=\"unordered\"><item><caption>o</caption><content styleCode=\"bold\">Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including lorazepam tablets.</content> These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. <content styleCode=\"bold\">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.</content></item><item><caption>o</caption><content styleCode=\"bold\">You can develop an addiction even if you take lorazepam tablets exactly as prescribed by your healthcare provider.</content></item><item><caption>o</caption><content styleCode=\"bold\">Take lorazepam tablets exactly as your healthcare provider prescribed.</content></item><item><caption>o</caption>Do not share your lorazepam tablets with other people.</item><item><caption>o</caption>Keep lorazepam tablets in a safe place and away from children.</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Physical dependence and withdrawal reactions. </content>Lorazepam tablets can cause physical dependence and withdrawal reactions. <list listType=\"unordered\"><item><caption>o</caption><content styleCode=\"bold\">Do not suddenly stop taking lorazepam tablets.</content> Stopping lorazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual movements, responses or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. <content styleCode=\"bold\">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.</content></item><item><caption>o</caption><content styleCode=\"bold\">Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months,</content> including anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears.</item><item><caption>o</caption>Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.</item><item><caption>o</caption>Do not take more lorazepam tablets than prescribed or take lorazepam tablets for longer than prescribed.</item></list></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are lorazepam tablets?</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Lorazepam tablets are a prescription medicine used: <list listType=\"unordered\"><item><caption>o</caption>to treat anxiety disorders</item><item><caption>o</caption>for the short-term relief of the symptoms of anxiety or anxiety that can happen with symptoms of depression</item><item><caption>o</caption><content styleCode=\"bold\">Lorazepam tablets are a federal controlled substance (CIV) because it contains lorazepam that can be abused or lead to dependence.</content> Keep lorazepam tablets in a safe place to prevent misuse and abuse. Selling or giving away lorazepam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.</item><item><caption>o</caption>It is not known if lorazepam tablets are safe and effective for use in children less than 12 years of age.</item><item><caption>o</caption>It is not known if lorazepam tablets are safe and effective for use for longer than 4 months.</item></list></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Do not take lorazepam tablets if you:</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>are allergic to lorazepam, other benzodiazepines, or any of the ingredients in lorazepam tablets. See the end of this Medication Guide for a complete list of ingredients in lorazepam tablets. </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before you take lorazepam tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have or have had depression, mood problems, or suicidal thoughts or behavior</item><item><caption>&#x2022;</caption>have a history of drug or alcohol abuse or addiction</item><item><caption>&#x2022;</caption>have lung disease or breathing problems (such as COPD, sleep apnea syndrome)</item><item><caption>&#x2022;</caption>have liver or kidney problems</item><item><caption>&#x2022;</caption>have or have had seizures</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. <list listType=\"unordered\"><item><caption>o</caption> Taking lorazepam tablets late in pregnancy may cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone), and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems). </item><item><caption>o</caption>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with lorazepam tablets. </item><item><caption>o</caption>There is a pregnancy registry for women who take lorazepam tablets during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with lorazepam tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visiting https://womensmentalhealth.org/pregnancyregistry/. </item></list></item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. Lorazepam passes into your breast milk. <list listType=\"unordered\"><item><caption>o</caption>Breastfeeding during treatment with lorazepam tablets may cause your baby to have sleepiness, feeding problems, and decreased weight gain. </item><item><caption>o</caption> Talk to your healthcare provider about the best way to feed your baby if you take lorazepam tablets.</item></list></item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.   Taking lorazepam tablets with certain other medicines can cause side effects or affect how well lorazepam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take lorazepam tablets?</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Take lorazepam tablets exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how much lorazepam tablets to take and when to take it.</item><item><caption>&#x2022;</caption>If you take too much lorazepam tablets, call your healthcare provider or go to the nearest hospital emergency room right away.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of lorazepam tablets?</content>   <content styleCode=\"bold\">Lorazepam tablets may cause serious side effects, including:</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">See &#x201C;What is the most important information I should know about lorazepam tablets?&#x201D;</content></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Lorazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills.</content><list listType=\"unordered\"><item><caption>o</caption>Do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam tablets affects you.</item><item><caption>o</caption><content styleCode=\"bold\">Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam tablets without first talking to your healthcare provider.</content> When taken with alcohol or drugs that cause sleepiness or dizziness, lorazepam tablets may make your sleepiness or dizziness much worse.</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Depression.</content> Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam tablets.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of lorazepam tablets include:</content>   &#x2022; sedation &#x2022; dizziness &#x2022; weakness &#x2022; unsteadiness   These are not all the possible side effects of lorazepam tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.   </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store lorazepam tablets?</content>   </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store lorazepam tablets in a tightly closed container at room temperature between 20&#xB0; to 25&#xB0;C (68&#xB0; to 77&#xB0;F). </item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Keep lorazepam tablets and all medicines out of the reach of children.</content></item></list><paragraph>  </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of lorazepam tablets</content>   Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lorazepam tablets for a condition for which it was not prescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about lorazepam tablets that is written for health professionals. </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in lorazepam tablets? </content>   <content styleCode=\"bold\">Active ingredient:</content> lorazepam <content styleCode=\"bold\">Inactive ingredients:</content> anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.   Distributed by: <content styleCode=\"bold\">Aurobindo Pharma USA, Inc.</content> 279 Princeton-Hightstown Road  East Windsor, NJ 08520   Manufactured by: <content styleCode=\"bold\">Aurobindo Pharma Limited</content> Hyderabad-500 032, India   For more information, call Aurobindo Pharma USA, Inc. at 1-866-850-2876. </paragraph></td></tr></tbody></table>"],"controlled_substance":["Controlled Substance Lorazepam tablets contains lorazepam, a Schedule IV controlled substance."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems. Lorazepam is readily absorbed with an absolute bioavailability of 90%. Peak concentrations in plasma occur approximately 2 hours following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. Lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable central nervous system (CNS) activity in animals. The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to 6 months. Studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of 1.5 to 3 mg of lorazepam Injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age."],"indications_and_usage":["INDICATIONS AND USAGE Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."],"information_for_patients":["Information for Patients Advise the patient to read the FDA-approved patient labeling ( Error! Hyperlink reference not valid. ). Risks from Concomitant Use with Opioids Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when lorazepam is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see and ). Abuse, Misuse, and Addiction Inform patients that the use of lorazepam even at recommended doses, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug (see and DRUG ABUSE AND DEPENDENCE ). Withdrawal Reactions Inform patients that the continued use of lorazepam may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of lorazepam may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of lorazepam may require a slow taper (see and DRUG ABUSE AND DEPENDENCE ). Pregnancy Advise pregnant females that use of lorazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see and ). Instruct patients to inform their healthcare provider if they are pregnant. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy (see ). Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs (see )."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg tablets are available. The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day. For anxiety, most patients require an initial dose of 2 to 3 mg/day given two times a day or three times a day. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated. The dosage of lorazepam tablets should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see and DRUG ABUSE AND DEPENDENCE: Dependence )."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Controlled Substance Lorazepam tablets contains lorazepam, a Schedule IV controlled substance. Abuse Lorazepam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see ). The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol). Dependence Physical Dependence Lorazepam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see ). To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (see and WARNINGS ). Acute Withdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures and suicidality. Protracted Withdrawal Syndrome Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re‑-emergence or continuation of symptoms for which the benzodiazepine was being used. Tolerance Tolerance to lorazepam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of lorazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines."],"spl_product_data_elements":["Lorazepam Lorazepam LORAZEPAM LORAZEPAM ANHYDROUS LACTOSE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLACRILIN POTASSIUM White to off white Flat-faced beveled edge U33"],"package_label_principal_display_panel":["PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 mg NDC 68788-7428 Rx only Lorazepam Tablets, USP 1 mg CIV PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO Repackaged by Preferred Pharmaceuticals, Inc. Lorazepam Tablets USP 1mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an 18-month study with lorazepam. No studies regarding mutagenesis have been performed."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":["WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). • The use of benzodiazepines, including lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS ). • The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage ( DOSAGE AND ADMINISTRATION and WARNINGS )."],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"13461 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"13327 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"12116 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"10353 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"10149 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"9237 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"8838 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"8660 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"8648 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"8559 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Sedation","drugRate":"15.9%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"6.9%","severity":"common","organSystem":""},{"effect":"Weakness","drugRate":"4.2%","severity":"common","organSystem":""},{"effect":"Unsteadiness","drugRate":"3.4%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Alcohol intoxication","Angle-closure glaucoma","At risk for aspiration","Breastfeeding (mother)","Central nervous system depression","Chronic lung disease","Decreased respiratory function","Depressive disorder","Disease of liver","Hepatic encephalopathy","Hepatic failure","Hypoalbuminemia","Kidney disease","Liver function tests abnormal","Open-angle glaucoma","Porphyria","Pregnancy, function","Severe chronic obstructive pulmonary disease","Sleep apnea","Substance abuse","Suicidal thoughts","Syncope"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Respiratory depression","drugRate":"","severity":"serious"},{"effect":"Apnea","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Coma","drugRate":"","severity":"serious"},{"effect":"Anaphylacticoid reactions","drugRate":"","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"","severity":"serious"},{"effect":"Pancytopenia","drugRate":"","severity":"serious"},{"effect":"Suicidal ideation/attempt","drugRate":"","severity":"serious"},{"effect":"Hepatotoxicity (jaundice, increase in bilirubin, increase in liver transaminases)","drugRate":"","severity":"serious"},{"effect":"Worsening of sleep apnea","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT03180632","NCT02671760","NCT03110900","NCT06852469","NCT06004115","NCT00972985","NCT07173231","NCT05317000","NCT04828226","NCT01121055","NCT01272778","NCT05606224","NCT01556932","NCT05338099","NCT06752616","NCT06591091","NCT04646135","NCT00429702","NCT02362256","NCT00621478","NCT00720421","NCT06223191","NCT01391962","NCT00337792","NCT02374567","NCT04156464","NCT07428681","NCT00714194","NCT00011297","NCT00523185","NCT00123578","NCT00587964","NCT01019681","NCT03300947","NCT05964647","NCT06496854","NCT01566539","NCT00158873","NCT00721526","NCT02648776","NCT01843868","NCT01198353","NCT02462109","NCT00715039","NCT01827293","NCT01893632","NCT01111942","NCT01810458","NCT01204255","NCT03012815"],"aliases":["Ativan"],"patents":[{"type":"Formulation","number":"8999393","applicant":"ALMATICA PHARMA LLC","territory":"US","tradeName":"LOREEV XR","expiryDate":"2034-01-08"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0450/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$16","description":"LORAZEPAM 0.5 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=lorazepam","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:58.822764+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:56:58.822680+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:04.472843+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:56:57.935315+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lorazepam","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:04.788036+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:53.989602+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:53.989633+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNIN","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:53.989643+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:57:06.652862+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: GABA-A receptor; anion channel positive allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:06.024392+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL580/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:05.496607+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203572","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:56:53.989647+00:00"}},"allNames":"ativan","offLabel":[],"timeline":[],"aiSummary":"Lorazepam (Ativan) is an intermediate-acting benzodiazepine approved in 1977. IV form is first-line for status epilepticus. No active metabolites make it safer in elderly/liver disease. Available generically. Schedule IV controlled substance.","brandName":"Ativan","companyId":"unknown","ecosystem":[],"mechanism":{"target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","novelty":"","modality":"Small molecule","drugClass":"Benzodiazepine [EPC]","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:09.290923+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Wyeth/Pfizer)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"lorazepam","indications":{"approved":[{"name":"Absence seizure","diseaseId":"absence-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anxiety","diseaseId":"anxiety","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Atonic seizure","diseaseId":"atonic-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Induce Anterograde Amnesia","diseaseId":"induce-anterograde-amnesia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lennox-Gastaut syndrome","diseaseId":"lennox-gastaut-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myoclonic seizure","diseaseId":"myoclonic-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Panic disorder","diseaseId":"panic-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sedation as Adjunct to Anesthesia","diseaseId":"sedation-as-adjunct-to-anesthesia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Status epilepticus","diseaseId":"status-epilepticus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03180632","phase":"Phase 2","title":"Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: a Randomized Double Blinded Study","status":"COMPLETED","sponsor":"St. Justine's Hospital","isPivotal":false,"enrollment":98,"indication":"Anxiety","completionDate":"2018-06-01"},{"nctId":"NCT02671760","phase":"Phase 2","title":"A Randomized, Double-Blind, Single-Dose Study to Assess the Pharmacodynamic Effects of SM-1 Versus Comparator and Placebo in a 5 Hour Phase Advance Model of Insomnia in Adults Who Suffer From Short-Te","status":"COMPLETED","sponsor":"Sequential Medicine Ltd","isPivotal":false,"enrollment":39,"indication":"Short-term Insomnia","completionDate":"2016-06"},{"nctId":"NCT03110900","phase":"Phase 4","title":"A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation","status":"TERMINATED","sponsor":"University of Arkansas","isPivotal":false,"enrollment":2,"indication":"Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use","completionDate":"2018-04-04"},{"nctId":"NCT06852469","phase":"Phase 4","title":"Individualized Computational Assessment of the Effects of GABA Receptor Modulation in Posttraumatic Stress Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":150,"indication":"Stress Disorders, Post-Traumatic","completionDate":"2029-06-30"},{"nctId":"NCT06004115","phase":"Phase 4","title":"Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression","status":"RECRUITING","sponsor":"Laureate Institute for Brain Research, Inc.","isPivotal":false,"enrollment":165,"indication":"Depression, Anxiety, Fear","completionDate":"2027-12-31"},{"nctId":"NCT00972985","phase":"NA","title":"Acute Effect of Three Neuroactive Drugs on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction Test","status":"COMPLETED","sponsor":"Orasi Medical, Inc.","isPivotal":false,"enrollment":15,"indication":"Healthy","completionDate":"2009-12"},{"nctId":"NCT07173231","phase":"NA","title":"Comparisons Between Virtual Reality and Hypno-Virtual Reality for Procedural Pain and Anxiety During a Diagnostic Hysteroscopy: A Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"St. Justine's Hospital","isPivotal":false,"enrollment":45,"indication":"Hysteroscopy, Anxiety","completionDate":"2026-03"},{"nctId":"NCT05317000","phase":"Phase 2","title":"A Window Trial of 5-Azacytidine or Nivolumab or Combination Nivolumab Plus 5-Azacytidine in Resectable HPV-Associated Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Barbara Burtness","isPivotal":false,"enrollment":50,"indication":"Squamous Cell Carcinoma of Head and Neck","completionDate":"2028-11-30"},{"nctId":"NCT04828226","phase":"Phase 4","title":"Clonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","isPivotal":false,"enrollment":130,"indication":"Major Depressive Disorder, Catatonia","completionDate":"2026-07-31"},{"nctId":"NCT01121055","phase":"Phase 4","title":"Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":372,"indication":"Patient Satisfaction for Bronchoscopy","completionDate":"2010-12"},{"nctId":"NCT01272778","phase":"NA","title":"Acute Effect of Four Doses of Lorazepam on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction™ Test","status":"UNKNOWN","sponsor":"Orasi Medical, Inc.","isPivotal":false,"enrollment":16,"indication":"Healthy Subjects","completionDate":"2011-04"},{"nctId":"NCT05606224","phase":"NA","title":"The Effects and Mechanisms of Mindfulness Intervention for Emotional Distress: a Multicenter Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Peking University","isPivotal":false,"enrollment":200,"indication":"Emotional Disorder","completionDate":"2023-08-30"},{"nctId":"NCT01556932","phase":"NA","title":"A Randomized Trial of the Effectiveness of Topical \"ABH Gel\" (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) Versus Placebo in Patients With Nausea","status":"COMPLETED","sponsor":"Virginia Commonwealth University","isPivotal":false,"enrollment":22,"indication":"Nausea, Vomiting","completionDate":"2014-05"},{"nctId":"NCT05338099","phase":"Phase 1","title":"Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)","status":"COMPLETED","sponsor":"ENCell","isPivotal":false,"enrollment":7,"indication":"Duchenne Muscular Dystrophy","completionDate":"2022-12-28"},{"nctId":"NCT06752616","phase":"Phase 2","title":"Advancing the Quality of Treatment and Care for Acute Agitation in Emergency Psychiatry","status":"RECRUITING","sponsor":"Lone Baandrup","isPivotal":true,"enrollment":132,"indication":"Agitation","completionDate":"2027-12"},{"nctId":"NCT06591091","phase":"Phase 2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":80,"indication":"Depression","completionDate":"2026-03"},{"nctId":"NCT04646135","phase":"Phase 2","title":"Not for Profit, Monocentric, Open Label Trial of Lorazepam, Randomized to Three Different Sequences of Boli and Continuous Infusion, for Sedation of Children Aged ≥1 and <12 Years Admitted in Intensiv","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","isPivotal":false,"enrollment":9,"indication":"Analgesia","completionDate":"2021-12"},{"nctId":"NCT00429702","phase":"Phase 2","title":"Phase II Randomized, Double-Blinded Study of an Antiemetic Pump, Using Benadryl®, Avitan® and Decadron® (BAD), for Children Receiving Moderately or Highly Emetogenic Chemotherapy","status":"TERMINATED","sponsor":"University of South Florida","isPivotal":false,"enrollment":7,"indication":"Nausea, Vomiting","completionDate":"2009-11"},{"nctId":"NCT02362256","phase":"NA","title":"The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism With Naltrexone and Sedation","status":"COMPLETED","sponsor":"Vilnius University","isPivotal":false,"enrollment":60,"indication":"Opiate Addiction","completionDate":"2014-09"},{"nctId":"NCT00621478","phase":"Phase 2","title":"Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","isPivotal":true,"enrollment":259,"indication":"Status Epilepticus","completionDate":"2012-05"},{"nctId":"NCT00720421","phase":"Phase 1","title":"A Phase 1, Single Centre, Single Dose, Double-blind, Double-dummy, Four-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroence","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":16,"indication":"Healthy Volunteer","completionDate":"2008-08"},{"nctId":"NCT06223191","phase":"NA","title":"Comparing Brief Negotiated Interview, Narrative Interview, and Standard Care to Reduce Readmission: A 2024 Clinical Trial in Substance Use Disorder Patients at Santa Rosita Psychiatric Specialties Hos","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional Autonoma de Honduras","isPivotal":false,"enrollment":150,"indication":"Substance Use Disorders, Substance Withdrawal","completionDate":"2024-09-15"},{"nctId":"NCT01391962","phase":"Phase 2","title":"A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":34,"indication":"Sarcoma, Alveolar Soft Part","completionDate":"2026-01-16"},{"nctId":"NCT00337792","phase":"NA","title":"A Randomized Clinical Trial Comparing Oral Conscious Sedation With Intravenous Conscious Sedation for First Trimester Surgical Abortion","status":"TERMINATED","sponsor":"Planned Parenthood League of Massachusetts","isPivotal":false,"enrollment":132,"indication":"Undesired Pregnancy","completionDate":"2007-07"},{"nctId":"NCT02374567","phase":"Phase 3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":407,"indication":"Dementia, Depression","completionDate":"2017-06-28"},{"nctId":"NCT04156464","phase":"Phase 4","title":"Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit","status":"UNKNOWN","sponsor":"OSF Healthcare System","isPivotal":false,"enrollment":142,"indication":"Alcohol Withdrawal, Alcohol Withdrawal Delirium","completionDate":"2022-03-01"},{"nctId":"NCT07428681","phase":"Phase 4","title":"Preventive Administration of Lorazepam in Critically Ill Patients With High Anttila-Index to Reduce the Incidence of Intensive Care Delirium: a Single-centre, Randomized, Controlled Clinical Trial - t","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":260,"indication":"Delirium Confusional State","completionDate":"2029-02"},{"nctId":"NCT00714194","phase":"EARLY/Phase 1","title":"The Effect of Daily Interruption of Continuous Sedation on the Occurrence of Delirium and Perception of Sleep in ICU Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":52,"indication":"Delirium, Sleep Perception","completionDate":"2009-09"},{"nctId":"NCT00011297","phase":"Phase 2","title":"Alcohol Research Center - Treatment and Implications","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","isPivotal":false,"enrollment":160,"indication":"Alcoholism","completionDate":"2005-12"},{"nctId":"NCT00523185","phase":"NA","title":"A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal","status":"COMPLETED","sponsor":"Stanford University","isPivotal":false,"enrollment":55,"indication":"Alcohol Withdrawal","completionDate":"2004-11"},{"nctId":"NCT00123578","phase":"Phase 1","title":"GHB: Effects, Withdrawal and Treatment","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":0,"indication":"Substance-Related Disorders","completionDate":"2008-08"},{"nctId":"NCT00587964","phase":"Phase 2","title":"Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":51,"indication":"Brain Metastasis, Bladder Cancer","completionDate":"2009-01"},{"nctId":"NCT01019681","phase":"Phase 1","title":"Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia","status":"TERMINATED","sponsor":"Richard Burt, MD","isPivotal":false,"enrollment":1,"indication":"Critical Limb Ischemia","completionDate":"2014-01"},{"nctId":"NCT03300947","phase":"Phase 1","title":"Psilocybin for Treatment of Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"University of Arizona","isPivotal":false,"enrollment":15,"indication":"Obsessive-compulsive Disorder (OCD)","completionDate":"2023-12-30"},{"nctId":"NCT05964647","phase":"Phase 1","title":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":20,"indication":"Healthy","completionDate":"2025-06-30"},{"nctId":"NCT06496854","phase":"Phase 2","title":"Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","isPivotal":false,"enrollment":0,"indication":"Pain, IUD","completionDate":"2026-01"},{"nctId":"NCT01566539","phase":"NA","title":"The Biological Basis of Individual Variation in Social Cooperation","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":707,"indication":"Healthy","completionDate":"2016-11"},{"nctId":"NCT00158873","phase":"Phase 4","title":"A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":224,"indication":"Sedation","completionDate":""},{"nctId":"NCT00721526","phase":"Phase 4","title":"Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder","status":"COMPLETED","sponsor":"University of New Mexico","isPivotal":false,"enrollment":41,"indication":"Alcohol Dependence, Anxiety Disorder","completionDate":"2012-08"},{"nctId":"NCT02648776","phase":"N/A","title":"Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly; A Prospective Cohort Study at a Taiwanese Academic Medical Center","status":"UNKNOWN","sponsor":"China Medical University Hospital","isPivotal":false,"enrollment":1400,"indication":"Sleep Disorders","completionDate":"2018-12"},{"nctId":"NCT01843868","phase":"NA","title":"A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP.","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","isPivotal":false,"enrollment":0,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2015-06"},{"nctId":"NCT01198353","phase":"Phase 4","title":"Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","isPivotal":false,"enrollment":67,"indication":"Schizophrenia, Schizoaffective Disorder","completionDate":"2013-12"},{"nctId":"NCT02462109","phase":"Phase 1","title":"Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study","status":"COMPLETED","sponsor":"Makerere University","isPivotal":false,"enrollment":16,"indication":"Catatonia, Nodding Syndrome","completionDate":"2013-03"},{"nctId":"NCT00715039","phase":"NA","title":"A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Ins","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":169,"indication":"Anxiety Disorders","completionDate":"2004-05"},{"nctId":"NCT01827293","phase":"Phase 3","title":"Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","isPivotal":true,"enrollment":210,"indication":"Peripheral Vertigo.","completionDate":"2013-06"},{"nctId":"NCT01893632","phase":"Phase 2","title":"Gabapentin Treatment of Benzodiazepine Dependence","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":2,"indication":"Benzodiazepine Dependence","completionDate":"2016-04-01"},{"nctId":"NCT01111942","phase":"EARLY/Phase 1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","isPivotal":false,"enrollment":4,"indication":"Head and Neck Cancer","completionDate":"2014-01"},{"nctId":"NCT01810458","phase":"N/A","title":"Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency","status":"COMPLETED","sponsor":"University of Florida","isPivotal":false,"enrollment":109,"indication":"Liver Fibrosis, Alpha-1 Antitrypsin Deficiency","completionDate":"2019-09"},{"nctId":"NCT01204255","phase":"NA","title":"Absorption of \"ABH Gel\" (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) From the Skin of Normal Volunteers","status":"COMPLETED","sponsor":"Virginia Commonwealth University","isPivotal":false,"enrollment":11,"indication":"Healthy","completionDate":"2011-05-17"},{"nctId":"NCT03012815","phase":"Phase 4","title":"A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":88,"indication":"Alcohol Withdrawal Syndrome","completionDate":"2021-03-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Two to three times daily","formulation":"Tablet, Injectable, Oral concentrate"},"crossReferences":{"unii":"O26FZP769L","rxcui":"6470","splId":"22212bf6-1414-4b32-bc67-25d614c357ee","chemblId":"CHEMBL580","pubchemSID":"145006"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4625,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"1977-09-30","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-10-13T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":null,"application_number":"ANDA071591"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-03-19T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"NDA018140"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-06-15T00:00:00.000Z","mah":"PHARM ASSOC","brand_name_local":null,"application_number":"ANDA090260"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-18T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA217598"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-07-24T00:00:00.000Z","mah":"GRAVITI PHARMS","brand_name_local":null,"application_number":"ANDA218597"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8999393","territory":"US","patent_type":"Formulation","expiry_date":"2034-01-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"pricingByCountry":[{"country_code":"UN","currency":"USD","price_amount":"16.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Un","currency":"USD","price_amount":"16.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:09.290923+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}